Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?

doi:10.1016/j.ajur.2022.03.005

Asian Journal of Urology, 2022, 9 (3): 206-207 doi: 10.1016/j.ajur.2022.03.005

Editorials

Current Issue | Archive | Adv Search

Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?

Emilio F. Giunta^a,Pasquale Rescigno^a,*(

),Roberto Pili^b

^aInterdisciplinary Group for Translational Research and Clinical Trials, Urological Cancers (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy
^bDivision of Hematology and Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA

Abstract
Related Citation (0)

[1]	Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract 2022; 18:187e96.
[2]	Vartolomei MD, Matei DV, Renne G, Tringali VM, Crișan N, Musi G, et al. Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. Minerva Urol Nefrol 2019; 71:31e7. doi: 10.23736/S0393-2249.18.03006-0 pmid: 30230293
[3]	Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794e9. doi: 10.1200/JCO.2008.21.4809
[4]	Dias Carneiro APC, Marques Monteiro FS, Soares A. PBRM 1 mutations as a predictive biomarker for immunotherapy in metastatic renal cell carcinoma: a systematic review. Kidney Cancer 2021; 5:79e92. doi: 10.3233/KCA-210111
[5]	Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 2020;26:1733e41.
[6]	McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24:749e57. doi: 10.1038/s41591-018-0053-3 pmid: 29867230
[7]	D’Costa NM, Cina D, Shrestha R, Bell RH, Lin YY, Asghari H, et al. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Sci Rep 2020; 10: 2026. https://doi.org/10.1038/s41598-020-58804-y. doi: 10.1038/s41598-020-58804-y
[8]	Barata PC, Gulati S, Elliott A, Rao A, Hammers HJ, Quinn DI, et al. Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP 1 alterations in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2021; 39(Suppl. 6):343. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.343.